TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headac... ( LA JOLLA Calif. June 23 /- Torrey...)

HOME >> BIOLOGY >> TECHNOLOGY

TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society

Date:6/23/2008

LA JOLLA, Calif., June 23 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that Dr. Neil Kurtz, President and Chief Executive Officer, will present data obtained from the Phase IIb study that evaluated the safety, tolerability and efficacy of three doses of tezampanel given subcutaneously for treatment of acute migraine at the 50th Annual Scientific Meeting of the American Headache Society in Boston on Saturday, June 28th at 2:00pm, Eastern.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity and rigidity, xerostomia and cognitive disorders. The company is currently developing four product candidates: two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists. Further information is available at http://www.torreypinestherapeutics.com.

Company Contact: Media Contact:

Paul Schneider David Schull

TorreyPines Therapeutics, Inc. Russo Partners, LLC

858-623-5665, x125 212-845-4271

pschneider@torreypinestherapeutics.com david.schull@russopartnersllc.com

Investor Contact:

Rhonda C
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:12/1/2009)...ovides services to three out of top five ,global p... Rochester, NY (PRWEB) December 1, 2009 -- iCardi... cardiac core lab services and QT analysis, announ...as selected iCardiac as a preferred vendor of ECG ...utomated QT(sm) and Dynamic QT beat-to-beat(sm) se...

(Date:11/30/2009)...n international team of applied scientists from Ha...onstrated compact, multibeam, and multi-wavelength...t spectrum (infrared). By contrast, typical lasers...ngth. The innovative multibeam lasers have potenti...sensing pollution monitoring, optical wireless, an...

(Date:11/30/2009)...ewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX...ay that the company will be presenting at the 21st... 2009 at 12:30 pm local time at The New York Palac...the company,s business strategy, research and deve...to the live audio only presentation can be accesse...

(Date:11/30/2009)...OS ANGELES, Nov. 30 /PRNewswire-Asia-FirstCall/ --... Board: CYXN; ,China Yongxin,Pharmaceuticals, or ,... and,retailer of pharmaceuticals in Northeastern C... for distribution of medicines on the Essential Dr...y formalized the nation,s Essential Drug,List whic...

Breaking Biology Technology:Another Top Five Pharmaceutical Company Selects iCardiac as Preferred Provider of ECG Core Lab Services 2 Scientists demonstrate multibeam, multi-functional lasers 2 NOVAVAX to Present at the Piper Jaffray 21st Annual Health Care Conference 2 China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 2 China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 3

[0] Another Top Five Pharmaceutical Company Selects iCardiac as Preferred Provider of ECG Core Lab Services [0] Scientists demonstrate multibeam, multi-functional lasers [0] NOVAVAX to Present at the Piper Jaffray 21st Annual Health Care Conference [0] China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List

... Increasing Case Volumes Drive 78 Percent Revenue ...o the Prior Year Period , , ALISO VIEJO, Calif., ...emier anatomic pathology and molecular testing ser...the pharmaceutical industry, today reported prelim... year ended December 31, 2008. Financial results ...

...arch 11 XTL Biopharmaceuticals Ltd. (Nasdaq: XT...nary General Meetings ("EGMs") were postponed for ...ation due to the absence of a quorum. The postpone... Kiryat Weizmann Science Park, Rehovot, Israel 761... 18, 2009. , , Any proxy votes received at any ti...

...H, Switzerland, March 11 Simbionix,the world,s le... VirtaMed, a,Swiss medical engineering company, an...mbionix will exclusively distribute, market, and p...ed virtual reality hysteroscopy simulator. , S...ors for minimal,invasive surgery. "This new agreem...

Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008 XTL Biopharmaceuticals Ltd. Extraordinary General Meetings Postponed Until March 18, 2009 Simbionix Increases Product Offerings for OB/GYN Physicians

(Date:11/30/2009)...ntific organisation is needed to monitor the commi...t Copenhagen to cut their deforestation rates, acc... Existing government agencies and research groups ...atellite images of the Earth,s surface collected e... paper published by Dr Alan Grainger in the Proce...

(Date:11/30/2009)... Clemson University researchers Ron Falta and Larr...Protection Agency grant to study the safe storage ... deep below the earth,s surface. , With carbon d...d to be the leading cause of global warming, geolo...g alternatives for reducing emissions using curren...

(Date:11/30/2009)...ase is available in German . , The DFG has ... Research Centres as of 1 January 2010. This decis...ttee in Bonn. The new centres will initially be fu...n addition, 20 percent overhead funding for indire...he centres, research topics range from modern pros...

[0] World forest observatory needed to monitor vital role of forests in climate deal [0] Clemson researchers receive EPA grant to study carbon emission storage [0] DFG approves funding for 17 new collaborative research centers

...overed a new technique for turning embryonic stem ...what could prove a significant breakthrough in the... University of Manchester team, working with colle... genetically manipulate the stem cells so that the...iption factor. , Stem cells have the ability to b...

...f Pittsburgh of UPMC a national leader in the use...or children in heart failure is part of a collabo...on grant from the National Institutes of Health (N...cifically for small children. , VADs are mechanic...e heart and offer lifesaving support, most often a...

...end bird feeders in their backyards each year, oft... survey of research on the topic finds that feedin...birds. , Published as a Frontiers in Ecology an...ology.org ), the meta-analysis led by Gillian Robb...rhop (University of Exeter, UK) reviewed results f...

Other Biology News:Stem cell breakthrough offers diabetes hope 2 Children's Hospital leads projects to develop nation's first heart assist devices for young children 2 Children's Hospital leads projects to develop nation's first heart assist devices for young children 3 Food for thought 2

Stem cell breakthrough offers diabetes hope Children's Hospital leads projects to develop nation's first heart assist devices for young children Food for thought

10% Normal Goat Serum from Invitrogen

GeneRacer Kit with SuperScript II RT and Zero Blunt TOPO PCR Cloning kit for Sequencing from Invitrogen

Goat Anti-Mouse Wnt-9b Affinity Purified Polyclonal Antibody, Unconjugated from R&D Systems

Chloride Colorimetric Assay Kit, QuantiChrom from BioAssay Systems

Biology Products:

10% Normal Goat Serum from Invitrogen GeneRacer Kit with SuperScript II RT and Zero Blunt TOPO PCR Cloning kit for Sequencing from Invitrogen Goat Anti-Mouse Wnt-9b Affinity Purified Polyclonal Antibody, Unconjugated from R&D Systems Chloride Colorimetric Assay Kit, QuantiChrom from BioAssay Systems

TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headac...( LA JOLLA Calif. June 23 /- Torrey...)